Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  2/13/2018
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 2/13/2018
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  2/13/2018
Decatur Memorial Hospital
mi
from
Decatur, IL
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 2/13/2018
Decatur Memorial Hospital
mi
from
Decatur, IL
Click here to add this to my saved trials
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  2/13/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 2/13/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  2/13/2018
Nebraska Methodist Hospital
mi
from
Omaha, NE
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 2/13/2018
Nebraska Methodist Hospital
mi
from
Omaha, NE
Click here to add this to my saved trials
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  2/13/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 2/13/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  2/13/2018
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 2/13/2018
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  2/13/2018
Case Western Reserve Univ
mi
from
Cleveland, OH
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 2/13/2018
Case Western Reserve Univ
mi
from
Cleveland, OH
Click here to add this to my saved trials
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  2/13/2018
Cleveland Clinic Cancer Center at Fairview Hospital
mi
from
Cleveland, OH
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 2/13/2018
Cleveland Clinic Cancer Center at Fairview Hospital
mi
from
Cleveland, OH
Click here to add this to my saved trials
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  2/13/2018
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 2/13/2018
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  2/13/2018
Lake University Ireland Cancer Center
mi
from
Mentor, OH
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 2/13/2018
Lake University Ireland Cancer Center
mi
from
Mentor, OH
Click here to add this to my saved trials
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  2/13/2018
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 2/13/2018
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  2/13/2018
Sanford Cancer Center-Oncology Clinic
mi
from
Sioux Falls, SD
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 2/13/2018
Sanford Cancer Center-Oncology Clinic
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  2/13/2018
Sanford USD Medical Center - Sioux Falls
mi
from
Sioux Falls, SD
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 2/13/2018
Sanford USD Medical Center - Sioux Falls
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  2/13/2018
Northwest Hospital
mi
from
Seattle, WA
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 2/13/2018
Northwest Hospital
mi
from
Seattle, WA
Click here to add this to my saved trials
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  2/13/2018
Pacific Gynecology Specialists
mi
from
Seattle, WA
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 2/13/2018
Pacific Gynecology Specialists
mi
from
Seattle, WA
Click here to add this to my saved trials
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  2/13/2018
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 2/13/2018
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Click here to add this to my saved trials
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  2/13/2018
University of Washington Medical Center
mi
from
Seattle, WA
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 2/13/2018
University of Washington Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  2/13/2018
UCSF Medical Center at Mount Zion
mi
from
San Francisco, CA
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 2/13/2018
UCSF Medical Center at Mount Zion
mi
from
San Francisco, CA
Click here to add this to my saved trials
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  2/13/2018
Florida Hospital Orlando
mi
from
Orlando, FL
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 2/13/2018
Florida Hospital Orlando
mi
from
Orlando, FL
Click here to add this to my saved trials
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  2/13/2018
Maine Medical Center-Bramhall Campus
mi
from
Portland, ME
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 2/13/2018
Maine Medical Center-Bramhall Campus
mi
from
Portland, ME
Click here to add this to my saved trials
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  2/13/2018
Novant Health Presbyterian Medical Center
mi
from
Charlotte, NC
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 2/13/2018
Novant Health Presbyterian Medical Center
mi
from
Charlotte, NC
Click here to add this to my saved trials
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  2/13/2018
Hillcrest Hospital Cancer Center
mi
from
Mayfield Heights, OH
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 2/13/2018
Hillcrest Hospital Cancer Center
mi
from
Mayfield Heights, OH
Click here to add this to my saved trials
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  2/13/2018
Women and Infants Hospital
mi
from
Providence, RI
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 2/13/2018
Women and Infants Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  2/13/2018
Saint Vincent Hospital and Health Care Center
mi
from
Indianapolis, IN
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 2/13/2018
Saint Vincent Hospital and Health Care Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  2/13/2018
Union Hospital of Cecil County
mi
from
Elkton, MD
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 2/13/2018
Union Hospital of Cecil County
mi
from
Elkton, MD
Click here to add this to my saved trials
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  2/13/2018
Carolinas Medical Center / Levine Cancer Institute
mi
from
Charlotte, NC
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 2/13/2018
Carolinas Medical Center / Levine Cancer Institute
mi
from
Charlotte, NC
Click here to add this to my saved trials
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  2/13/2018
Sanford NCI Community Oncology Research Program of the North Central Plains
mi
from
Sioux Falls, SD
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 2/13/2018
Sanford NCI Community Oncology Research Program of the North Central Plains
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Acupuncture in Treating Dry Mouth Caused By Radiation Therapy in Patients With Head and Neck Cancer
A Phase III Prospective Randomized Trial of Acupuncture for Treatment of Radiation-Induced Xerostomia in Patients With Head and Neck Cancer
Status: Enrolling
Updated:  2/13/2018
CCOP Research Base Sites
mi
from
Houston, TX
Acupuncture in Treating Dry Mouth Caused By Radiation Therapy in Patients With Head and Neck Cancer
A Phase III Prospective Randomized Trial of Acupuncture for Treatment of Radiation-Induced Xerostomia in Patients With Head and Neck Cancer
Status: Enrolling
Updated: 2/13/2018
CCOP Research Base Sites
mi
from
Houston, TX
Click here to add this to my saved trials
MR-Guided Laser Interstitial Thermal Therapy in Treating Patients With Prostate Cancer
Phase II Evaluation of MR-Guided Laser Induced Interstitial Thermal Therapy (LITT) for Prostate Cancer
Status: Enrolling
Updated:  2/13/2018
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
MR-Guided Laser Interstitial Thermal Therapy in Treating Patients With Prostate Cancer
Phase II Evaluation of MR-Guided Laser Induced Interstitial Thermal Therapy (LITT) for Prostate Cancer
Status: Enrolling
Updated: 2/13/2018
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Computed Tomography Versus Standard 2D Mammography Versus 3D Tomosynthesis
Computed Tomography Versus Standard 2D Mammography Versus 3D Tomosynthesis
Status: Enrolling
Updated:  2/13/2018
UC Davis Medical Center
mi
from
Sacramento, CA
Computed Tomography Versus Standard 2D Mammography Versus 3D Tomosynthesis
Computed Tomography Versus Standard 2D Mammography Versus 3D Tomosynthesis
Status: Enrolling
Updated: 2/13/2018
UC Davis Medical Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
An Exercise Intervention for Prostate Cancer Patients Receiving Androgen Deprivation Therapy
An Exercise Intervention to Mitigate Side-Effects Related to Androgen Deprivation Therapy Among Prostate Cancer Survivors.
Status: Enrolling
Updated:  2/13/2018
Office of Minority Health and Health Disparities Research
mi
from
Washington,
An Exercise Intervention for Prostate Cancer Patients Receiving Androgen Deprivation Therapy
An Exercise Intervention to Mitigate Side-Effects Related to Androgen Deprivation Therapy Among Prostate Cancer Survivors.
Status: Enrolling
Updated: 2/13/2018
Office of Minority Health and Health Disparities Research
mi
from
Washington,
Click here to add this to my saved trials
Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer
Expanded Access to 11C Choline PET/CT and 11C Choline PET/MR for Staging of Recurrent Prostate Cancer With Comparison Study of CT and MR Modalities
Status: Enrolling
Updated:  2/13/2018
Decatur Memorial Hospital
mi
from
Decatur, IL
Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer
Expanded Access to 11C Choline PET/CT and 11C Choline PET/MR for Staging of Recurrent Prostate Cancer With Comparison Study of CT and MR Modalities
Status: Enrolling
Updated: 2/13/2018
Decatur Memorial Hospital
mi
from
Decatur, IL
Click here to add this to my saved trials
A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult Participants With Hepatocellular Carcinoma (HCC)
A Phase 1b, Proof of Mechanism, Open-label Study of RO7070179, a Hypoxia-inducible Factor 1a (HIF1A) mRNA Antagonist in Adult Subjects With Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  2/13/2018
Indiana University
mi
from
Indianapolis, IN
A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult Participants With Hepatocellular Carcinoma (HCC)
A Phase 1b, Proof of Mechanism, Open-label Study of RO7070179, a Hypoxia-inducible Factor 1a (HIF1A) mRNA Antagonist in Adult Subjects With Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 2/13/2018
Indiana University
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult Participants With Hepatocellular Carcinoma (HCC)
A Phase 1b, Proof of Mechanism, Open-label Study of RO7070179, a Hypoxia-inducible Factor 1a (HIF1A) mRNA Antagonist in Adult Subjects With Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  2/13/2018
Laura and Isaac Perlmutter Cancer Center @ NYU Langone
mi
from
New York, NY
A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult Participants With Hepatocellular Carcinoma (HCC)
A Phase 1b, Proof of Mechanism, Open-label Study of RO7070179, a Hypoxia-inducible Factor 1a (HIF1A) mRNA Antagonist in Adult Subjects With Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 2/13/2018
Laura and Isaac Perlmutter Cancer Center @ NYU Langone
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult Participants With Hepatocellular Carcinoma (HCC)
A Phase 1b, Proof of Mechanism, Open-label Study of RO7070179, a Hypoxia-inducible Factor 1a (HIF1A) mRNA Antagonist in Adult Subjects With Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  2/13/2018
NYU Langone Medical Center; Bellevue Hospital
mi
from
New York, NY
A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult Participants With Hepatocellular Carcinoma (HCC)
A Phase 1b, Proof of Mechanism, Open-label Study of RO7070179, a Hypoxia-inducible Factor 1a (HIF1A) mRNA Antagonist in Adult Subjects With Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 2/13/2018
NYU Langone Medical Center; Bellevue Hospital
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult Participants With Hepatocellular Carcinoma (HCC)
A Phase 1b, Proof of Mechanism, Open-label Study of RO7070179, a Hypoxia-inducible Factor 1a (HIF1A) mRNA Antagonist in Adult Subjects With Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  2/13/2018
Weill-Cornell Medical College
mi
from
New York, NY
A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult Participants With Hepatocellular Carcinoma (HCC)
A Phase 1b, Proof of Mechanism, Open-label Study of RO7070179, a Hypoxia-inducible Factor 1a (HIF1A) mRNA Antagonist in Adult Subjects With Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 2/13/2018
Weill-Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult Participants With Hepatocellular Carcinoma (HCC)
A Phase 1b, Proof of Mechanism, Open-label Study of RO7070179, a Hypoxia-inducible Factor 1a (HIF1A) mRNA Antagonist in Adult Subjects With Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  2/13/2018
Columbia University Medical Center
mi
from
New York, NY
A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult Participants With Hepatocellular Carcinoma (HCC)
A Phase 1b, Proof of Mechanism, Open-label Study of RO7070179, a Hypoxia-inducible Factor 1a (HIF1A) mRNA Antagonist in Adult Subjects With Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 2/13/2018
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult Participants With Hepatocellular Carcinoma (HCC)
A Phase 1b, Proof of Mechanism, Open-label Study of RO7070179, a Hypoxia-inducible Factor 1a (HIF1A) mRNA Antagonist in Adult Subjects With Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  2/13/2018
Gabrail Cancer Center
mi
from
Canton, OH
A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult Participants With Hepatocellular Carcinoma (HCC)
A Phase 1b, Proof of Mechanism, Open-label Study of RO7070179, a Hypoxia-inducible Factor 1a (HIF1A) mRNA Antagonist in Adult Subjects With Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 2/13/2018
Gabrail Cancer Center
mi
from
Canton, OH
Click here to add this to my saved trials
A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult Participants With Hepatocellular Carcinoma (HCC)
A Phase 1b, Proof of Mechanism, Open-label Study of RO7070179, a Hypoxia-inducible Factor 1a (HIF1A) mRNA Antagonist in Adult Subjects With Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  2/13/2018
Ohio State University
mi
from
Columbus, OH
A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult Participants With Hepatocellular Carcinoma (HCC)
A Phase 1b, Proof of Mechanism, Open-label Study of RO7070179, a Hypoxia-inducible Factor 1a (HIF1A) mRNA Antagonist in Adult Subjects With Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 2/13/2018
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Pharmacokinetics of Entospletinib in Adults With Normal and Impaired Liver Function
A Phase 1, Open-Label, Multiple Dose Study to Evaluate the Pharmacokinetics of Entospletinib in Subjects With Normal and Impaired Hepatic Function
Status: Enrolling
Updated:  2/13/2018
Clinical Pharmacology of Miami (CPMI)
mi
from
Miami, FL
Pharmacokinetics of Entospletinib in Adults With Normal and Impaired Liver Function
A Phase 1, Open-Label, Multiple Dose Study to Evaluate the Pharmacokinetics of Entospletinib in Subjects With Normal and Impaired Hepatic Function
Status: Enrolling
Updated: 2/13/2018
Clinical Pharmacology of Miami (CPMI)
mi
from
Miami, FL
Click here to add this to my saved trials
Pharmacokinetics of Entospletinib in Adults With Normal and Impaired Liver Function
A Phase 1, Open-Label, Multiple Dose Study to Evaluate the Pharmacokinetics of Entospletinib in Subjects With Normal and Impaired Hepatic Function
Status: Enrolling
Updated:  2/13/2018
Orlando Clinical Research Center
mi
from
Orlando, FL
Pharmacokinetics of Entospletinib in Adults With Normal and Impaired Liver Function
A Phase 1, Open-Label, Multiple Dose Study to Evaluate the Pharmacokinetics of Entospletinib in Subjects With Normal and Impaired Hepatic Function
Status: Enrolling
Updated: 2/13/2018
Orlando Clinical Research Center
mi
from
Orlando, FL
Click here to add this to my saved trials
Pharmacokinetics of Entospletinib in Adults With Normal and Impaired Liver Function
A Phase 1, Open-Label, Multiple Dose Study to Evaluate the Pharmacokinetics of Entospletinib in Subjects With Normal and Impaired Hepatic Function
Status: Enrolling
Updated:  2/13/2018
DaVita Clinical Research
mi
from
Minneapolis, MN
Pharmacokinetics of Entospletinib in Adults With Normal and Impaired Liver Function
A Phase 1, Open-Label, Multiple Dose Study to Evaluate the Pharmacokinetics of Entospletinib in Subjects With Normal and Impaired Hepatic Function
Status: Enrolling
Updated: 2/13/2018
DaVita Clinical Research
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Pharmacokinetics of Entospletinib in Adults With Normal and Impaired Liver Function
A Phase 1, Open-Label, Multiple Dose Study to Evaluate the Pharmacokinetics of Entospletinib in Subjects With Normal and Impaired Hepatic Function
Status: Enrolling
Updated:  2/13/2018
Texas Liver Institute
mi
from
San Antonio, TX
Pharmacokinetics of Entospletinib in Adults With Normal and Impaired Liver Function
A Phase 1, Open-Label, Multiple Dose Study to Evaluate the Pharmacokinetics of Entospletinib in Subjects With Normal and Impaired Hepatic Function
Status: Enrolling
Updated: 2/13/2018
Texas Liver Institute
mi
from
San Antonio, TX
Click here to add this to my saved trials
Pharmacokinetics of Entospletinib in Adults With Normal and Impaired Liver Function
A Phase 1, Open-Label, Multiple Dose Study to Evaluate the Pharmacokinetics of Entospletinib in Subjects With Normal and Impaired Hepatic Function
Status: Enrolling
Updated:  2/13/2018
APEX GmBH
mi
from
Munich,
Pharmacokinetics of Entospletinib in Adults With Normal and Impaired Liver Function
A Phase 1, Open-Label, Multiple Dose Study to Evaluate the Pharmacokinetics of Entospletinib in Subjects With Normal and Impaired Hepatic Function
Status: Enrolling
Updated: 2/13/2018
APEX GmBH
mi
from
Munich,
Click here to add this to my saved trials
Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
A Phase 1/2, Open-Label Study of the JAK2 Inhibitor INCB018424 Administered Orally to Patients With Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (Post-PV/ET)
Status: Enrolling
Updated:  2/13/2018
Clinical Research Facility
mi
from
Rochester, MN
Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
A Phase 1/2, Open-Label Study of the JAK2 Inhibitor INCB018424 Administered Orally to Patients With Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (Post-PV/ET)
Status: Enrolling
Updated: 2/13/2018
Clinical Research Facility
mi
from
Rochester, MN
Click here to add this to my saved trials
Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
A Phase 1/2, Open-Label Study of the JAK2 Inhibitor INCB018424 Administered Orally to Patients With Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (Post-PV/ET)
Status: Enrolling
Updated:  2/13/2018
Clinical Research Facility
mi
from
Houston, TX
Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
A Phase 1/2, Open-Label Study of the JAK2 Inhibitor INCB018424 Administered Orally to Patients With Primary Myelofibrosis (PMF) and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (Post-PV/ET)
Status: Enrolling
Updated: 2/13/2018
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer
A Phase II Study of Combined VEGF Inhibitor (Bevacizumab + Sorafenib) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE06-109
Status: Enrolling
Updated:  2/13/2018
Medical and Surgical Specialists, LLC
mi
from
Galesburg, IL
A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer
A Phase II Study of Combined VEGF Inhibitor (Bevacizumab + Sorafenib) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE06-109
Status: Enrolling
Updated: 2/13/2018
Medical and Surgical Specialists, LLC
mi
from
Galesburg, IL
Click here to add this to my saved trials
A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer
A Phase II Study of Combined VEGF Inhibitor (Bevacizumab + Sorafenib) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE06-109
Status: Enrolling
Updated:  2/13/2018
Oncology Hematology Associates of SW Indiana
mi
from
Evansville, IN
A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer
A Phase II Study of Combined VEGF Inhibitor (Bevacizumab + Sorafenib) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE06-109
Status: Enrolling
Updated: 2/13/2018
Oncology Hematology Associates of SW Indiana
mi
from
Evansville, IN
Click here to add this to my saved trials
A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer
A Phase II Study of Combined VEGF Inhibitor (Bevacizumab + Sorafenib) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE06-109
Status: Enrolling
Updated:  2/13/2018
Fort Wayne Oncology & Hematology, Inc
mi
from
Fort Wayne, IN
A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer
A Phase II Study of Combined VEGF Inhibitor (Bevacizumab + Sorafenib) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE06-109
Status: Enrolling
Updated: 2/13/2018
Fort Wayne Oncology & Hematology, Inc
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer
A Phase II Study of Combined VEGF Inhibitor (Bevacizumab + Sorafenib) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE06-109
Status: Enrolling
Updated:  2/13/2018
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer
A Phase II Study of Combined VEGF Inhibitor (Bevacizumab + Sorafenib) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE06-109
Status: Enrolling
Updated: 2/13/2018
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials